EMA (EU)
GUIDANCE FINAL
Concept paper on the revision of the guideline on the clinical evaluation of antifungal agents for the treatment and prophylaxis of invasive fungal disease
Published: 6/29/2026Detected: 6/29/2026
Summary preview
Updates EMA clinical evaluation expectations for antifungal agents to better support regulatory claims for treatment/prophylaxis of invasive fungal disease, with particular focus on rare/emerging pathogens, refractory…
Get the full analysis, free
Create a free account to see the complete summary, key takeaways, and why this matters for your products, and to get alerts like this by email.
Create free accountinfectious_disease
pediatrics
respiratory
clinical
safety
labeling
#invasive fungal disease
#antifungal agents
#rare and emerging pathogens
#refractory disease
#salvage therapy
Official Source Document Source Verified
Access the original document directly from EMA.
More from EMA (EU)
- Pharmacovigilance Risk Assessment Committee (PRAC): 23 - 26 November 202611/23/2026
- Seventeenth meeting of the industry stakeholder platform on the operation of the centralised procedure for human medicines11/20/2026
- EMA annual call with General Practitioner Organisations' representatives11/20/2026
- Digitalisation and artificial intelligence in pharmaceutical manufacturing: Quality Innovation Group (QIG) - Follow-up roundtable meeting11/18/2026
- Meeting of the Executive Steering Group on Shortages and Safety of Medicinal Products (MSSG) - November 202611/18/2026